SCHEMBL19663095

SCHEMBL19663095

CC(C)C(=O)NCCc1cn(C(C)C)nn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
CYP2C19 P33261 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.36
SPR P35270 1/20 0.36
CYP19A1 P11511 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.35
MEN1 O00255 1/20 0.35
NR2F2 P24468 1/20 0.35
RAB9A P51151 1/20 0.35
NQO2 P16083 1/20 0.34
MTNR1A P48039 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19655507 0.85 ANPEP (0.41)
SCHEMBL20997389 0.83 MEN1 (0.34) CYP2C19KMT2ACYP2D6CYP2C9TSHR
SCHEMBL23945860 0.79 GBA1 (0.45) RECQL
SCHEMBL26501075 0.79 CYP19A1 (0.33) KMT2ACYP19A1MEN1NR2F2RAB9A
SCHEMBL17324236 0.77 CYP19A1 (0.38) KMT2ACYP19A1MEN1
SCHEMBL24233268 0.76 CYP19A1 (0.40) CYP19A1
SCHEMBL26011534 0.76 KMT2A (0.39) KMT2AGAACYP19A1MEN1
SCHEMBL20073431 0.76 ALDH1A1 (0.39) KMT2ATSHRMEN1NR2F2RAB9A
SCHEMBL22790888 0.76 GBA1 (0.43) RECQLCYP2C19KMT2ACYP2D6CYP2C9
SCHEMBL14434944 0.75 CYP19A1 (0.42) CYP19A1MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-11241502-B2 Stable compositions of pegylated carfilzomib compounds AMGEN INC. (US) 2022-02-08 US disclosed
US-20190142957-A1 STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS AMGEN INC. 2019-05-16 US disclosed
US-20170340746-A1 PEGYLATED CARFILZOMIB COMPOUNDS AMGEN INC. 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340746-A1 PEGYLATED CARFILZOMIB COMPOUNDS MCL1, FCGRT, MAN2B1 RECQL 3256/4885CYP2C19 1839/4885KMT2A 745/4885
US-20190142957-A1 STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS MCL1, PHOSPHO1, PSMB5 RECQL 3313/4885CYP2C19 634/4885KMT2A 775/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 RECQL 2668/4885CYP2C19 2991/4885KMT2A 2349/4885
US-11241502-B2 Stable compositions of pegylated carfilzomib compounds MCL1, PHOSPHO1, PSMB5 RECQL 3313/4885CYP2C19 634/4885KMT2A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.